Literature DB >> 3357144

Pharmacokinetics of intravenous metronidazole in neonates.

P Upadhyaya1, V Bhatnagar, N Basu.   

Abstract

Metronidazole is being extensively used in neonates for the prevention and treatment of anaerobic infections. However, detailed pharmacokinetic studies are not available. Thirty neonates receiving intravenous metronidazole 7.5 mg/kg at eight-hour intervals were studied with serial blood levels. The levels increased up to the third day of treatment and then reached a plateau. Neonates less than seven days of age showed higher levels than older infants. Septicemic neonates, however, showed continually rising levels. The half-life of metronidazole was 22.3 to 22.5 hours, approximately twice that in adults. This study indicates that neonates handle the drug differently than adults and may require it in lesser doses or at greater time intervals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3357144     DOI: 10.1016/s0022-3468(88)80736-x

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  9 in total

1.  The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Authors:  Robin E Pearce; Michael Cohen-Wolkowiez; Mario R Sampson; Gregory L Kearns
Journal:  Drug Metab Dispos       Date:  2013-06-27       Impact factor: 3.922

Review 2.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

Review 3.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 4.  New antibiotic dosing in infants.

Authors:  Leslie C Pineda; Kevin M Watt
Journal:  Clin Perinatol       Date:  2014-11-27       Impact factor: 3.430

5.  Neonatal early onset sepsis due to anaerobies: myth or realities: a review of medical record in one neonatal centre.

Authors:  Herve B Chatue Kamga
Journal:  J Clin Neonatol       Date:  2013-04

6.  Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants.

Authors:  Michael Cohen-Wolkowiez; Mario Sampson; Barry T Bloom; Antonio Arrieta; James L Wynn; Karen Martz; Barrie Harper; Gregory L Kearns; Edmund V Capparelli; David Siegel; Daniel K Benjamin; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

Review 7.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

8.  Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants.

Authors:  Michael Cohen-Wolkowiez; Daniele Ouellet; P Brian Smith; Laura P James; Ashley Ross; Janice E Sullivan; Michele C Walsh; Arlene Zadell; Nancy Newman; Nicole R White; Angela D M Kashuba; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

9.  Dosing antibiotics in neonates: review of the pharmacokinetic data.

Authors:  Nazario D Rivera-Chaparro; Michael Cohen-Wolkowiez; Rachel G Greenberg
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.